Pathology of HPV-Associated Head and Neck Carcinomas: Recent Data and Perspectives for the Development of Specific Tumor Markers

Sastre-Garau, X.; Harlé, Alexandre

doi:10.3389/fonc.2020.528957

Cited by 17 publications

(17 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…46 By analyzing the immune infiltrate in HNC, studies demonstrated that HPV-positive cancers had greater CD8+ T cell infiltrate and PD-L1 expression than HPV-negative tumors. 47 , 48 …”

Section: Resultsmentioning

confidence: 99%

“…In regard to genetic differences, HPV-positive tumors are characterized by recurrent mutations of PTEN, TRAF3 (TNF receptor-associated factor 3), and PIK3CA and focal amplification of E2F1, while HPV-negative tumors demonstrate a high rate of TP53 mutations and abrogation of the G1/S checkpoint via CDKN2A/B deletion and/or CCND1 amplification. 47 …”

Section: Resultsmentioning

confidence: 99%

“…46 By analyzing the immune infiltrate in HNC, studies demonstrated that HPV-positive cancers had greater CD8+ T cell infiltrate and PD-L1 expression than HPVnegative tumors. 47,48 Despite having a more extensive nodal disease, patients with HPV-related OPC demonstrate better treatment response and have a more favorable prognosis than patients with HPV-negative OPC. [43][44][45] In regard to genetic differences, HPV-positive tumors are characterized by recurrent mutations of PTEN, TRAF3 (TNF receptor-associated factor 3), and PIK3CA and focal amplification of E2F1, while HPV-negative tumors demonstrate a high rate of TP53 mutations and abrogation of the G1/S checkpoint via CDKN2A/B deletion and/or CCND1 amplification.…”

Section: Dovepressmentioning

confidence: 99%

See 2 more Smart Citations

Human Papillomavirus-Associated Head and Neck Cancers. Where are We Now? A Systematic Review

Pinkiewicz¹,

Dorobisz²,

Zatoński³

2022

CMAR

View full text Add to dashboard Cite

Background Human papillomavirus targets the skin and mucous membranes, producing benign hyperplastic lesions and precancerous and cancerous lesions. An increasing number of head and neck cancersin particular, oropharyngeal squamous cell carcinoma, laryngeal squamous cell carcinoma, and oral squamous cell carcinoma, are attributable to HPV infection. HPV-induced HNCs typically affect younger, nonsmoking patients with no prior history of heavy alcohol use, more extensive sexual history, and higher socioeconomic status. Aim The purpose of the review is to present the most recent and well-established findings concerning HPV-induced head and neck cancers and consequently to provide medical specialists with essential information regarding the epidemiology, the role of HPV in HNC cancerogenesis, prevention, diagnosis, and treatment. Material and Methods All authors independently have searched The EMbase, Medline/Pubmed, and Cochrane databases by using the following keywords “head and neck cancer”, “human papillomavirus”, “HPV”, “HPV biology”, “oropharyngeal squamous cell carcinoma”, “carcinogenesis”, “transoral surgery”, “robotic surgery”. The last search was conducted in March 2022. The references of the publications of interest were also screened for relevant papers. There were no limitations in regard to the publication date. Conclusion Aiming to avoid the epidemic of HPV-induced HNC, it is paramount to improve the access to vaccination as well as resolve parental concerns regarding vaccine safety. Physicians should rely on reduced-dose radiation and aim to reduce the overall treatment time. Thanks to a more elaborate understanding of the genomic background of HPV-induced HNC, precision medicine could become a relevant part of patients’ management. In comparison to traditional techniques and non-operative treatment, transoral robotic surgery (TORS) offers similar oncologic and functional outcomes, with a possible benefit on long-term quality of life. However, more research is needed to establish clear guidelines indicating when TORS resections should be supported with adjuvant therapy.

show abstract

“…46 By analyzing the immune infiltrate in HNC, studies demonstrated that HPV-positive cancers had greater CD8+ T cell infiltrate and PD-L1 expression than HPV-negative tumors. 47 , 48 …”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Dovepressmentioning

confidence: 99%

See 1 more Smart Citation

Human Papillomavirus-Associated Head and Neck Cancers. Where are We Now? A Systematic Review

Pinkiewicz¹,

Dorobisz²,

Zatoński³

2022

CMAR

View full text Add to dashboard Cite

show abstract

“…Besides, the comprehensive genomic landscape in HPV-positive HNSCC is remarkably different from smoking-related HNSCC ( 32 – 34 ). In general, HPV-positive HNSCCs exhibited a relatively low mutational burden (2.28 mutations per Mb vs. 4.83 mutations per Mb in HPV-negative cases) ( 32 ), a high proliferative index, a frequent alteration in the PIK3CA pathway, compared to HPV-negative HNSCCs ( 35 ). A current study reported that the most frequent mutation exhibited in an OPSCC cohort with 948 subjects was TP53 (33%), followed by PIK3CA (17%) and KMT2D (10.6%); and TP53 was more commonly mutated in the HPV-negative group (mutation rate: 49% vs. 10%, P < 0.0005) ( 36 ).…”

Section: Hpv and Opsccmentioning

confidence: 99%

An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

Oropharyngeal squamous cell carcinoma (OPSCC) is an uncommon malignancy worldwide. Remarkably, the rising incidence of OPSCC has been observed in many developed countries over the past few decades. On top of tobacco smoking and alcohol consumption, human papillomavirus (HPV) infection has become a major etiologic factor for OPSCC. The radiotherapy-based or surgery-based systemic therapies are recommended equally as first-line treatment, while chemotherapy-based strategy is applied to advanced diseases. Immunotherapy in head and neck squamous cell carcinoma (HNSCC) is currently under the spotlight, especially for patients with advanced diseases. Numerous researches on programmed death-1/programmed death-ligand 1 checkpoint inhibitors have proven beneficial to patients with metastatic HNSCC. In 2016, nivolumab and pembrolizumab were approved as the second-line treatment for advanced metastatic HNSCC by the USA Food and Drug Administration. Soon after, in 2019, the USA Food and Drug Administration approved pembrolizumab as the first-line treatment for patients with unresectable, recurrent, and metastatic HNSCC. It has been reported that HPV-positive HNSCC patients were associated with increased programmed death-ligand 1 expression; however, whether HPV status indicates different treatment outcomes among HNSCC patients treated with immunotherapy has contradicted. Notably, HPV-positive OPSCC exhibits a significantly better clinical response to primary treatment (i.e., radiotherapy, surgery, and chemotherapy) and a more desirable prognosis compared to the HPV-negative OPSCC. This review summarizes the current publications on immunotherapy in HNSCC/OPSCC patients and discusses the impact of HPV infection in immunotherapeutic efficacy, providing an update on the immune landscape and future perspectives in OPSCC.

show abstract

“…Various studies have been carried out to develop the examination designs. The method of examination, the molecular targets, and the biological sources used were considered in those studies [11,106,107].…”

Section: Dental Calculus: Novel Promising Biosource For Hpv-induced Oral Cancer Studymentioning

confidence: 99%

The Presence of HPV in Dental Calculus: It’s Role in Pathogenesis of Oral and Cervical Cancer

Widyaputra¹,

Pranata²,

Setiawan³

et al. 2021

Cervical Cancer - A Global Public Health Treatise

View full text Add to dashboard Cite

Human papillomavirus (HPV) infection accounts for approximately 5.2% of the worldwide human cancer burden. Molecular epidemiologic evidence clearly indicates that certain types of HPV are the principal cause of both cervical and oral cancers. Major oncoproteins E6 and E7 can inactivate p53 and pRB proteins because it happened genome instability and dysregulation host cell cycles. This virus is an epithelial tropism, vulnerable area mainly at the basal layer and epithelial stem cell, because it still has a high proliferation capacity, so it can support the replication of the virus. Virions bind initially to the glycosaminoglycan (GAG) chains of heparan sulphate proteoglycan (HSPG). More than 99% cervical cancer arise at the cervical transformation zone. In oral cavity, exposed areas of the basal layer will be very susceptible to HPV infection. The HPV presence in the oral area is considered as one of the etiologics of oral cancer in those who do not have bad habits such as smoking, betel chewing, or poor oral hygiene. Our study successfully identified HPV type 58 in dental calculus. Dental calculus, calcified oral plaque biofilm, has been shown to be an abundant, nearly ubiquitous, and long-term reservoir of the ancient oral microbiome, including bacteria, archaea, eukaryote, and viruses. During biomineral maturation process, several biological contents around the oral region should be trapped, including the exfoliated virus contained cells. Dental calculus is a promising source of HPV and carcinogens molecules in the oral cavity and could be used as a biomarker for early detection.

show abstract

Pathology of HPV-Associated Head and Neck Carcinomas: Recent Data and Perspectives for the Development of Specific Tumor Markers

Cited by 17 publications

References 87 publications

Human Papillomavirus-Associated Head and Neck Cancers. Where are We Now? A Systematic Review

Human Papillomavirus-Associated Head and Neck Cancers. Where are We Now? A Systematic Review

An Update on the Immunotherapy for Oropharyngeal Squamous Cell Carcinoma

The Presence of HPV in Dental Calculus: It’s Role in Pathogenesis of Oral and Cervical Cancer

Contact Info

Product

Resources

About